Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -101.66% is 18% above its 5-year average of -124.31%, near the high end of its 5-year range (-371.16%–-25.83%).
As of the fiscal period ended Tuesday, June 30, 2026. 10.66% above its 12-month average of -113.78%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -101.66%.
RETURN ON EQUITY (ROE)
-101.66%
RETURN ON EQUITY (ROE) AVG TTM
-113.78%
RETURN ON EQUITY (ROE) AVG 3Y
-151.55%
RETURN ON EQUITY (ROE) AVG 5Y
-124.31%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+10.66%
CURRENT VS 3Y AVG
+32.92%
CURRENT VS 5Y AVG
+18.22%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-38.25%
median of 444 covered companies
CURRENT VS SECTOR MEDIAN
-165.77%
vs the sector median at left
IN8bio, Inc.
Market Cap
$13.62M
Return on Equity (ROE)
-101.66%
TTM Avg
-113.78%
3Y Avg
-151.55%
5Y Avg
-124.31%
Market Cap
$13.55M
Return on Equity (ROE)
-186.95%
TTM Avg
1198.98%
3Y Avg
241.18%
5Y Avg
112.17%
Market Cap
$13.34M
Return on Equity (ROE)
-74.73%
TTM Avg
-265.78%
3Y Avg
-138.63%
5Y Avg
-109.18%
Market Cap
$14.28M
Return on Equity (ROE)
-69.47%
TTM Avg
-55.64%
3Y Avg
-44.95%
5Y Avg
-41.56%
Market Cap
$12.63M
Return on Equity (ROE)
N/A
TTM Avg
-201.97%
3Y Avg
-21.23%
5Y Avg
365.72%
Market Cap
$12.46M
Return on Equity (ROE)
N/A
TTM Avg
-162.71%
3Y Avg
-135.96%
5Y Avg
-98.83%
Market Cap
$15.20M
Return on Equity (ROE)
N/A
TTM Avg
54.00%
3Y Avg
301.36%
5Y Avg
162.15%
Market Cap
$15.20M
Return on Equity (ROE)
-42.72%
TTM Avg
-65.53%
3Y Avg
-58.02%
5Y Avg
-43.63%
Market Cap
$11.95M
Return on Equity (ROE)
N/A
TTM Avg
-43.97%
3Y Avg
-160.70%
5Y Avg
-188.29%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| IN8bio, Inc. (INAB) | $13.62M | -101.66% | -113.78% | -151.55% | -124.31% |
| Vyome Holdings, Inc. (HIND)vs › | $13.55M | -186.95% | 1198.98% | 241.18% | 112.17% |
| Cellectar Biosciences, Inc. (CLRB)vs › | $13.34M | -74.73% | -265.78% | -138.63% | -109.18% |
| Citius Pharmaceuticals, Inc. (CTXR)vs › | $14.28M | -69.47% | -55.64% | -44.95% | -41.56% |
| Dare Bioscience, Inc. (DARE)vs › | $12.63M | N/A | -201.97% | -21.23% | 365.72% |
| Cytosorbents Corporation (CTSO)vs › | $12.46M | N/A | -162.71% | -135.96% | -98.83% |
| Karyopharm Therapeutics Inc. (KPTI)vs › | $15.20M | N/A | 54.00% | 301.36% | 162.15% |
| Pasithea Therapeutics Corp. (KTTA)vs › | $15.20M | -42.72% | -65.53% | -58.02% | -43.63% |
| CytoMed Therapeutics Limited (GDTC)vs › | $11.95M | N/A | -43.97% | -160.70% | -188.29% |
| IRIDEX Corporation (IRIX)vs › | $11.94M | -97.47% | -90.15% | -205.18% | -136.35% |
ROE
-101.7%
ROA
-85.8%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -101.66% |
| 2026-03-31 | -83.32% |
| 2025-12-31 | -70.54% |
| 2025-09-30 | -156.63% |
| 2025-06-30 | -156.77% |
| 2025-03-31 | -197.63% |
| 2024-12-31 | -210.23% |
| 2024-09-30 | -371.16% |
| 2024-06-30 | -234.62% |
| 2024-03-31 | -177.13% |
| 2023-12-31 | -120.33% |
| 2023-09-30 | -170.10% |
| 2023-06-30 | -139.63% |
| 2023-03-31 | -178.11% |
| 2022-12-31 | -125.47% |
| 2022-09-30 | -89.88% |
| 2022-06-30 | -84.93% |
| 2022-03-31 | -56.14% |
| 2021-12-31 | -38.38% |
| 2021-09-30 | -25.83% |
| 2021-06-30 | -68.85% |
| 2021-03-31 | -56.55% |
| 2020-12-31 | -46.71% |
| 2020-06-30 | -917.84% |
